share_log

22nd Century Group to Announce Second Quarter 2024 Results on August 13, 2024

22nd Century Group to Announce Second Quarter 2024 Results on August 13, 2024

22世紀集團將於2024年8月13日宣佈2024年第二季度業績。
newsfile ·  08/06 08:00

Mocksville, North Carolina--(Newsfile Corp. - August 6, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction and contract manufacturing, will host a webcast on Tuesday, August 13, 2024, at 8:00 AM ET to discuss its 2024 second quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

北卡羅來納州莫克斯維爾--(新聞稿公司 - 2024年8月6日)-- 22世紀集團股份有限公司 (NASDAQ: XXII),一家專注於尼古丁傷害緩解和合同製造的菸草製品公司,將於2024年8月13日星期二上午8:00 ET舉行網絡研討會,討論其2024年第二季度業績,這些業績將於當天早上6:00 ET通過新聞稿公佈。

During the webcast, Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer, will review financial results and discuss progress made in the recent months.

在網絡研討會期間,董事長兼首席執行官拉里·法伊斯通和首席財務官丹·奧托將回顧財務業績並討論近幾個月的進展情況。

The live and archived webcast will be accessible on the Events web page in the Company's Investor Relations section of the website, at . Please access the website at least 15 minutes prior to the start of the webcast to register and, if necessary, download and install any required software.

現場和歸檔的網絡研討會可以通過公司網站投資者關係部分的“事件”網頁進行訪問。請在網絡研討會開始前至少15分鐘訪問網站進行註冊,並在必要時下載和安裝所需的軟件。

About 22nd Century Group, Inc.

關於22世紀集團公司

22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction by offering tobacco products with 95% less nicotine, designed to improve health and wellness by helping smokers smoke less. Backed by comprehensive and extensively patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, the Company has pioneered the development of high-yield, proprietary reduced nicotine content (RNC) tobacco plants and clinically validated RNC cigarette products. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. The Company is a subsequent participating manufacturer under the Master Settlement Agreement ("MSA") and vertically integrated for the production of both its own products and contract manufacturing operations ("CMO"), which consist primarily of branded filtered cigars and conventional cigarettes.

22世紀集團股份有限公司 (NASDAQ: XXII) 是一家農業生物科技公司,專注於通過提供含有95%較少尼古丁的菸草產品以減少菸草危害,並旨在通過幫助吸菸者減少吸菸來改善健康和健康狀況。該公司通過對菸草植物中尼古丁生物合成活動進行全面和廣泛的專利技術調控,開創了高產量的專有減少尼古丁含量 (RNC) 菸草植物和經過臨床驗證的 RNC 菸捲產品的研發先河。該公司於2021年12月獲得了第一個和唯一授予可燃菸捲的 FDA 修改危險菸草產品 (MRTP) 許可。該公司是大衆和康卡斯特訴訟達成的大衆和康卡斯特協議的後續參與制造商,與自己的產品和合同製造業務 ("CMO") 垂直整合,其主要由品牌過濾雪茄和傳統香菸組成。

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

欲了解更多,請訪問 xxiicentury.com,在Twitter、領英和YouTube上了解我們公司的最新動態。

Learn more about VLN at tryvln.com.

了解有關VLN的更多信息,請訪問 tryvln.com。

Cautionary Note Regarding Forward-Looking Statements

關於前瞻性聲明的謹慎說明

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-Looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-Looking statements include, but are not limited to, statements regarding (i) our strategic alternatives and cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024 and Quarterly Report on Form 10-Q filed on May 15, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

除了歷史信息外,本新聞稿中包含的所有聲明、期望和假設都是前瞻性聲明,包括但不限於我們全年業務展望。前瞻性聲明通常包含“預計”、“相信”、“考慮”、“繼續”、“可能”、“估計”、“期望”、“探索”、“預見”、“目標”、“指導”、“打算”、“可能”、“計劃”、“潛力”、“預測”、“初步”、“可能的”、“項目”、“有前途的”、“尋求”、“應該”、“將”、“願意”等類似表達。前瞻性聲明包括但不限於有關 (i) 我們的戰略選擇和成本削減措施, (ii) 我們對監管執法的預期,包括我們獲得豁免新規定的能力, (iii) 我們的財務和營運業績以及 (iv) 我們對商業中斷保險索賠的預期。實際結果可能會因前瞻性聲明所述的明示或暗示的因素而有所不同。可能導致實際結果不同的重要因素在2024年3月28日提交的公司年報10-k中的"風險因素"中說明,以及2024年5月15日提交的季度報告10-Q中說明。本新聞稿中提供的所有信息都是截至此時此刻的,公司對這些前瞻性聲明不承擔更新的義務,除法律另有要求外。

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

投資者關係與媒體聯繫
Matt Kreps
投資者關係
22世紀集團
mkreps@xxiicentury.com
214-597-8200

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論